Showing results (2271-2280 of 2,317) with videos related to
Sort By:
Pageof 232
Journal of Hematology & Oncology|May 9, 2023
First-in-human phase I/Ib study of QL1706 (PSB205), a bifunctional PD1/CTLA4 dual blocker, in patients with advanced solid tumorsYuanyuan Zhao, Yuxiang Ma, Aimin Zang, et al.International Journal of Molecular Sciences|February 11, 2023
A Functional Polymorphism Downstream of Vitamin A Regulator Gene CYP26B1 Is Associated with Hand OsteoarthritisVivia Khosasih, Kai-Ming Liu, Chung-Ming Huang, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 14, 2023
HLA-I Evolutionary Divergence Confers Response to PD-1 Blockade plus Chemotherapy in Untreated Advanced Non-Small Cell Lung CancerTao Jiang, Qiqi Jin, Jiahao Wang, et al.Journal of Hematology & Oncology|April 18, 2020
A phase 3 study of rituximab biosimilar HLX01 in patients with diffuse large B-cell lymphomaYuankai Shi, Yongping Song, Yan Qin, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|July 5, 2025
Lazertinib Versus Osimertinib in Previously Untreated EGFR-Mutant Advanced NSCLC: A Randomized, Double-Blind, Exploratory Analysis From MARIPOSASe-Hoon Lee, Shun Lu, Hidetoshi Hayashi, et al.Med (New York, N.Y.)|April 12, 2025
Multidisciplinary expert consensus on diagnosis and treatment of multiple lung cancersKezhong Chen, Anwen Liu, Changli Wang, et al.Cancer Biology & Medicine|December 10, 2020
Current management of chemotherapy-induced neutropenia in adults: key points and new challenges: Committee of Neoplastic Supportive-Care (CONS), China Anti-Cancer Association Committee of Clinical Chemotherapy, China Anti-Cancer AssociationYi Ba, Yuankai Shi, Wenqi Jiang, et al.The Lancet. Respiratory Medicine|December 15, 2023
Sunvozertinib for patients in China with platinum-pretreated locally advanced or metastatic non-small-cell lung cancer and EGFR exon 20 insertion mutation (WU-KONG6): single-arm, open-label, multicentre, phase 2 trialMengzhao Wang, Yun Fan, Meili Sun, et al.Nature Medicine|June 1, 2024
Fruquintinib plus paclitaxel versus placebo plus paclitaxel for gastric or gastroesophageal junction adenocarcinoma: the randomized phase 3 FRUTIGA trialFeng Wang, Lin Shen, Weijian Guo, et al.Advances in Therapy|September 4, 2024
Efficacy and Safety of Biosimilar SCT510 Compared with Bevacizumab for the First-Line Treatment of Advanced Non-Squamous Non-Small Cell Lung Cancer: A Randomized, Double-Blind, Phase III StudyYing Cheng, Zhanyu Pan, Lin Wu, et al.Pageof 232